1. Fassel H, McGuinn C. Haemophilia: factoring in new therapies. Br J Haematol. 2021;194(5):835–50.
2. BioMarin Pharmaceutical Inc. First gene therapy for adults with severe hemophilia A, BioMarin's ROCTAVIAN™ (valoctocogene roxaparvovec), approved by European Commission (EC) [media release]. 24 Aug 2022. https://investors.biomarin.com/.
3. BioMarin Pharmaceutical Inc. BioMarin receives European orphan drug designation for BMN 270, first investigational AAV-factor VIII gene therapy for patients with hemophilia A [media release]. 24 Mar 2016. https://www.biomarin.com/.
4. BioMarin Pharmaceutical Inc. BioMarin receives orphan drug designation from FDA for first AAV-factor VIII gene therapy, BMN 270, for patients with hemophilia A [media release]. 1 Mar 2016. https://www.biomarin.com/.
5. BioMarin Pharmaceutical Inc. BioMarin receives access to priority medicines (PRIME) regulatory support from EMA for BMN 270 gene therapy in hemophilia A [media release]. 1 Feb 2017. https://www.biomarin.com/.